GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » Dividend-Payout-to-FFO

NKGN (NKGen Biotech) Dividend-Payout-to-FFO


View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.


NKGen Biotech Business Description

Traded in Other Exchanges
N/A
Address
3001 Daimler Street, Santa Ana, CA, USA, 92705
NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.